ViMRT
}  
 
Home   
< Docs   

 SARS_CoV_2 mutation literature information.


  SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.
 PMID: 34473242       2021       Clinical infectious diseases
Abstract: Among 9,048 people infected with SARS-CoV-2 between January-May, 2021 in Maryland, in regression-adjusted analysis, SARS-CoV-2 viruses carrying the spike protein mutation E484K were disproportionately prevalent among persons infected after full vaccination against COVID-19 as compared to infected persons who were not fully vaccinated (aOR 1.96, 95% CI, 1.36 to 2.83).


  Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2.
 PMID: 34478710       2021       The Journal of biological chemistry
Result: S1), notably mutations L452R (8.8%), E484K (7.7%), T478K (5.9%), S477N (2.2%), and N439K (1.2%), which are also found in other various VOCs and were shown to either increase infectivity or promote the evasion of antibody responses.


  Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.
 PMID: 34484190       2021       Frontiers in immunology
Introduction: In addition, several recent studies have focused on the neutralizing activity of vaccine-elicited humoral immunity against new circulating mutant lineages, including B.1.1.7 (United Kingdom, bearing mutations 69-70 del, 144 del, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H in the spike protein), B.1.429 (United States, bearing mutations S13I, W152C, L452R, and D614G in the spike protein), B.1.351(South Africa, bearing mutations D80A, D215G,  PMID: 34488546       2021       Expert review of vaccines
Introduction: P681R/P681H also exists in several variants under investigation in the United Kingdom, including A.23.1/E484K, B.1.1.7, and B1.318.


  Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures.
 PMID: 34493762       2021       Scientific reports
Result: Delta69-70, N501Y, and E484K, all present in the second group.


  Enzymatic Beacons for Specific Sensing of Dilute Nucleic Acid and Potential Utility for SARS-CoV-2 Detection.
 PMID: 34494022       2021       bioRxiv
Abstract: E-beacon prepared for the E484K variant of SARS-CoV-2 functioned with similar sensitivity.
Introduction: A second E-beacon was prepared for detecting the E484K mutation, which is present in certain alpha and all beta and gamma strains of SARS-CoV-2.
Introduction: Here Eb.19 (E484K) was mixed with either E484K target oligo (Figure 3C, top trace), with random oligonucleotide, E484 (WT) or an oligo corresponding to E484Q of the SARS-CoV-2 Kappa variant.


  A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern In Vitro and In Vivo.
 PMID: 34495697       2021       Journal of virology
Introduction: Using this strategy, we have successfully rescued Venus-and mCherry-expressing rSARS-CoV-2 USA/WA1/2020 (WA-1) and a new rSARS-CoV-2 strain expressing mCherry and containing mutations K417N, E484K, and N501Y present in the receptor binding domain (RBD) of the viral spike (S) glycoprotein of the South Africa (SA) B.1.351 (beta [beta]) VoC.
Result: Towards this objective, we generated an rSARS-CoV-2 containing the K417N, E484K, and N501Y mutations found in the S RBD of the SA strain of SARS-CoV-2 and expressing also mCherry, referred to as rSARS-CoV-2 mCh


  SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.
 PMID: 34495709       2021       Journal of clinical microbiology
Abstract: Of the 200 samples belonging to the B.1.575 lineage, 194 (97%) corresponded to the B.1.575.2 sublineage, which was related to the presence of the E484K mutation.
Abstract: We report the emergence and spread of a new SARS-CoV-2 variant within the B.1.575 lineage, containing the E484K mutation in the spike protein (named B.1.575.2), in a region in northern Spain in May and June 2021.
Method: At that time, we customized the TaqMan assay to detect SARS-CoV-2 spike protein with the N501Y, E484K, K417N, and K417T mutations.


  Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
 PMID: 34495817       2021       Journal of biomolecular structure & dynamics
Figure: (a) Native (control) spike (red) and E484K variant (blue), (b) Native spike (red) and N501Y variant (yellow), (c) Native spike (red) and multiple (K417N + E484K + N501Y) spike variant (green).
Figure: (a) Native spike (red) and E484K (blue) variant, (b) Native spike (red) and N501Y variant (yellow), (c) Native spike and multiple (K417N + E484K + N501Y) spike v


  SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels.
 PMID: 34499599       2021       Emerging infectious diseases
Introduction:
Introduction: E484K causes resistance to many class 2 RBD-directed antibodies, including bamlanivimab.
Introduction: E484K has been additionally reported in 1 of 6,011 B.1.617.1 (Kappa variant) sequences.



Browser Board

 Co-occurred Entities




   Filtrator